BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
about
Allogeneic stem cell transplantation in first complete remissionThe prognostic and functional role of microRNAs in acute myeloid leukemiaASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaDdx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML.GAS6 expression identifies high-risk adult AML patients: potential implications for therapyE-26 Transformation-specific Related Gene Expression and Outcomes in Cytogenetically Normal Acute Myeloid Leukemia: A Meta-analysis.Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.MiR-99a may serve as a potential oncogene in pediatric myeloid leukemiaThe Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemiaPrognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaClinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis.High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemiamiR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaThe Globalization of Cooperative Groups.CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.MiR-148a inhibits angiogenesis by targeting ERBB3.Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemiaClinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsHigh expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemiaA stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis.ETS-related gene is a novel prognostic factor in childhood acute lymphoblastic leukemia.SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.Gene expression profiling in MDS and AML: potential and future avenues.Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.Acute myeloid leukemia with normal cytogenetics.Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.Hox gene dysregulation in acute myeloid leukemia.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?MicroRNAs in Myeloid Hematological Malignancies.High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.
P2860
Q26996818-E563C280-F48F-42FE-8D61-F7C327A642D6Q27693865-769371FF-11C8-42D4-B498-BFBBADA197AEQ27851679-3DF69E91-A64F-44D0-A607-DBA97FAE99EAQ27851713-9D0146A9-AB22-4456-B66C-91D2D55A7D88Q30503129-11B6EFAD-65A4-41FD-AE56-47807FD42D2EQ33717707-689431A9-D693-4E94-825D-5F2069052AB3Q33776896-0A12C520-BAD5-4FCF-9247-98ACCD8AFB29Q34119417-73DA986E-83AA-4825-B07F-1D93BC06888DQ34193684-E15E1F36-EDEF-4A73-BBF6-2958C82F6AC3Q34251541-C64E3E29-9CCB-4338-B4D1-CDEBF021AB7AQ34766817-12EAA8B4-EA9F-4C52-85FE-033C486893D4Q34831106-D2B6B15E-AA2E-4BDB-94A1-5DDC7AA1A792Q35043364-22C8BF98-48F1-45BD-82B2-6900D56CD46FQ35152173-3C1F9C4B-5A90-4C95-8CF7-C11E757EC8E2Q35265946-FA1B7B4E-79F9-4B91-AEA9-B2FA3608CC5CQ35710995-4343EE61-5E41-4D8B-9F12-F7635F128683Q35741669-5DCF0671-882A-407B-80B7-F72E5543A923Q35781530-0762B257-CF02-4549-9C8D-A5914B5D200AQ35794120-651C7525-5425-4A4D-A931-DF2641038E19Q35922032-DB946837-85D0-4F23-ADDB-E47B3029BE8DQ36100455-574CFF8D-F64E-45C8-A204-87FB85F28F47Q36119749-6E072737-59B3-4CC1-A165-89C6D3FD79B0Q36249453-2E661A33-EC9B-4FFA-B99F-C142DE120D09Q36683208-4E5D8164-C6E1-4061-9FE6-A4306186E0ADQ36771874-527CECB7-9A3C-4F2F-AA1C-B4F318E17565Q37065843-B00BAE65-65C1-445F-BABF-179E831B17C7Q37085891-56A2E28C-9D53-4D15-A5F4-A6D3CFAAA8DBQ37298691-1BA6F1F6-C6D7-47B8-AD2E-A074A4D1511DQ37474559-A4A701C1-D92E-4EDE-B7A0-16382E93A299Q37575953-F3716D9F-E3DA-4D19-B0A8-8C9F9E8C0EBBQ37594153-CB595A4E-0FF4-4C42-9F08-E24576D53419Q37679943-0B9D0459-D09B-4D3E-B70D-F66744D11629Q37858877-E4000866-8029-4E3D-A9B8-5AC6B087D9F0Q37954583-3DEA1C40-B8DA-4BF0-81D3-3F40F67D13F0Q38027047-940AEF53-7F9A-4095-872E-47E50EE7DE74Q38062865-CDA5369B-490C-49F6-AEB2-0205E3B0A830Q38190116-080B8CFB-AB9A-4946-AFA0-1063F5D4D8A6Q38199056-AF4C74E7-F495-4245-B6E3-D1D941695951Q38599595-853B7009-732A-4053-A19F-B4EA1941AAF6Q38671635-01A713ED-DFAB-42D4-9C13-225DE7C8E32D
P2860
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BAALC and ERG expression level ...... er and Leukemia Group B study.
@ast
BAALC and ERG expression level ...... er and Leukemia Group B study.
@en
BAALC and ERG expression level ...... er and Leukemia Group B study.
@nl
type
label
BAALC and ERG expression level ...... er and Leukemia Group B study.
@ast
BAALC and ERG expression level ...... er and Leukemia Group B study.
@en
BAALC and ERG expression level ...... er and Leukemia Group B study.
@nl
prefLabel
BAALC and ERG expression level ...... er and Leukemia Group B study.
@ast
BAALC and ERG expression level ...... er and Leukemia Group B study.
@en
BAALC and ERG expression level ...... er and Leukemia Group B study.
@nl
P2093
P2860
P50
P921
P1433
P1476
BAALC and ERG expression level ...... er and Leukemia Group B study.
@en
P2093
Andrew J Carroll
Bayard L Powell
Dean Margeson
Heiko Becker
Jonathan E Kolitz
Joseph O Moore
Kelsi B Holland
Maria R Baer
Michael A Caligiuri
Michael D Radmacher
P2860
P304
P356
10.1182/BLOOD-2010-06-290536
P407
P50
P577
2010-09-14T00:00:00Z